SCHEDULE 13G/A: Highbridge Capital Management Discloses 3.7% Stake in Precision BioSciences via Warrants
Beneficial Ownership Report
Highbridge Capital Management, LLC has filed an amended Schedule 13G, reporting beneficial ownership of 3.7% of Precision BioSciences Inc.'s common stock, primarily through warrants.
Summary
- Highbridge Capital Management, LLC, an investment adviser, reported beneficial ownership of 406,250 shares of Precision BioSciences Inc. common stock.
- This stake represents 3.7% of the Issuer's total outstanding common stock.
- The reported shares are issuable upon the exercise of warrants directly held by the Highbridge Funds.
- The percentage ownership is calculated based on an aggregate of 10,481,931 shares of Common Stock outstanding as of March 20, 2025, as reported in Precision BioSciences Inc.'s Annual Report on Form 10-K.
- Highbridge Capital Management, LLC holds shared voting power and shared dispositive power over all 406,250 shares.
Sentiment
Score: 5
Explanation: Neutral. The document is a factual disclosure of an ownership stake and does not contain information that would inherently sway sentiment positively or negatively regarding the company's operational performance or future prospects.
Future Outlook
NA
Industry Context
This filing reflects an institutional investment firm's passive stake in a biotechnology company, which is a common occurrence in the sector as investors seek exposure to potential advancements in drug development or platform technologies.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can offer insights into institutional confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/20/2025 | Date as of which the total outstanding shares (10,481,931) of Precision BioSciences Inc. were reported in its Annual Report on Form 10-K. |
| 03/26/2025 | Date Precision BioSciences Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the SEC. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 04/25/2025 | Signature date of the Schedule 13G filing by Kirk Rule, Executive Director of Highbridge Capital Management, LLC. |
Keywords
Precision BioSciences Inc., Highbridge Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Investment Adviser, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.